` COLL (Collegium Pharmaceutical Inc) vs S&P 500 Comparison - Alpha Spread

COLL
vs
S&P 500

Over the past 12 months, COLL has underperformed S&P 500, delivering a return of -7% compared to the S&P 500's 9% growth.

Stocks Performance
COLL vs S&P 500

Loading
COLL
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
COLL vs S&P 500

Loading
COLL
S&P 500
Difference
www.alphaspread.com

Performance By Year
COLL vs S&P 500

Loading
COLL
S&P 500
Add Stock

Competitors Performance
Collegium Pharmaceutical Inc vs Peers

S&P 500
COLL
LLY
JNJ
NOVO B
ROG
Add Stock

Collegium Pharmaceutical Inc
Glance View

Market Cap
951.1m USD
Industry
Pharmaceuticals

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL Intrinsic Value
60.67 USD
Undervaluation 51%
Intrinsic Value
Price
Back to Top